SCHEMBL304535

SCHEMBL304535

[CH2]COC(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
TDP1 Q9NUW8 2/20 0.55
KMT2A Q03164 2/20 0.55
MAPK1 P28482 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SLC6A2 P23975 1/20 0.55
SLC6A3 Q01959 1/20 0.55
LMNA P02545 3/20 0.50
HCAR2 Q8TDS4 1/20 0.50
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
GFER P55789 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL37382 0.89 ALDH1A1 (0.68) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
Ammonia Solution, Strong SCHEMBL9998884 0.87 ALDH1A1 (0.65) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
Water SCHEMBL8217838 0.87 ALDH1A1 (0.65) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
Bicarbonate SCHEMBL29183459 0.87 ALDH1A1 (0.65) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL29254311 0.85 ALDH1A1 (0.53) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL3835760 0.82 ALDH1A1 (0.59) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL10184395 0.82 ALDH1A1 (0.59) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL454115 0.81 ALDH1A1 (0.63) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL48133 0.81 ALDH1A1 (0.63) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
Formaldehyde SCHEMBL28519982 0.81 ALDH1A1 (0.58) ALDH1A1TDP1KMT2AMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159227-B1 Two-photon absorption material and application thereof RICOH CO LTD (JP) 2014-08-06 EP claimed
EP-0333174-B1 Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1996-05-08 EP claimed
EP-0639195-A1 2-ACYLOXYCEPHEM DERIVATIVES AS ELASTASE INHIBITORS PHARMACIA & UPJOHN S.p.A. (IT) 1995-02-22 EP claimed
US-5283326-A Coupling azo and cyanine dyes; colorfastness, heat resistance SANDOZ AG (CH) 1994-02-01 US claimed
US-5187156-A D-Tryptophan- and Phenylalanine-containing tripeptides as tachykinin antagonists; asthma FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-02-16 US claimed
EP-0505413-A1 BETA-LACTAM DERIVATIVES. ERBA FARMITALIA (IT) 1992-09-30 EP claimed
EP-0333174-A2 Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-09-20 EP claimed
US-4837269-A FIBER-REACTIVE DISAZO DYES BASF AKTIENGESELLSCHAFT (DE) 1989-06-06 US claimed
US-4751288-A COLORFASTNESS BASF AKTIENGESELLSCHAFT (DE) 1988-06-14 US claimed
US-4619992-A IMPROVED COLORFASTNESS BASF AKTIENGESELLSCHAFT (DE) 1986-10-28 US claimed
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-07-02 US disclosed
CN-113967258-B FAP-activated therapeutic agents and related uses 塔夫茨大学信托人 2024-07-02 CN disclosed
CN-118109069-A Resin composition, cured product, and method for producing cured product 东京应化工业株式会社 2024-05-31 CN disclosed
CN-118108899-A Curable resin composition, cured product, and method for producing cured product 东京应化工业株式会社 2024-05-31 CN disclosed
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-03-12 US disclosed
EP-0087677-A1 Isothiazolazo dyestuffs BASF Aktiengesellschaft (DE) 1983-09-07 EP disclosed
US-4383945-A 4-Substituted-2-oxoazetidine compounds and processes for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-05-17 US disclosed
EP-0038087-A2 Beta-lactam containing compounds, their preparation and use BEECHAM GROUP PLC (GB) 1981-10-21 EP disclosed
EP-0035689-A1 4-Substituted-2-oxoazetidine compounds, processes for their preparation, and their use for preparing antibiotics FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-09-16 EP disclosed
EP-0008497-A1 Beta-lactam-containing compounds, their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1980-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 ALDH1A1 749/4885TDP1 322/4885KMT2A 3355/4885
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto FAP, FIBP, GOT1 ALDH1A1 323/4885TDP1 834/4885KMT2A 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.